Glasgow-Blatchford score
Glasgow-Blatchford score is a risk scoring tool used to predict the need for treatment in patients with upper gastrointestinal bleeding (UGIB). It was developed by Blatchford et al. in 2000 and is named after the city of Glasgow, where the study was conducted.
Overview[edit]
The Glasgow-Blatchford score is calculated based on several clinical and laboratory parameters, including blood urea nitrogen, hemoglobin, systolic blood pressure, pulse, presentation with melena, presentation with syncope, hepatic disease, and cardiac failure. The score ranges from 0 to 23, with higher scores indicating a higher risk of needing intervention.
Clinical Use[edit]
The Glasgow-Blatchford score is primarily used to identify patients with UGIB who are at low risk of needing intervention and can be safely managed as outpatients. It has been shown to have a high sensitivity for predicting the need for intervention, but its specificity is lower.
Scoring System[edit]
The scoring system is as follows:
- Blood urea nitrogen: 0-2 points
- Hemoglobin: 0-6 points
- Systolic blood pressure: 0-3 points
- Pulse: 0-2 points
- Presentation with melena: 1 point
- Presentation with syncope: 2 points
- Hepatic disease: 2 points
- Cardiac failure: 2 points
Limitations[edit]
While the Glasgow-Blatchford score is a useful tool for risk stratification in UGIB, it has some limitations. It does not take into account the patient's age or comorbidities, which can significantly affect the risk of needing intervention. Additionally, it requires laboratory testing, which may not be immediately available in all settings.
See Also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
